Bone Disorders Archives - MPR

Bone Disorders

FDA to Review Fedratinib for the Treatment of Myelofibrosis


The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for fedratinib (Celgene), an investigational agent being developed for the treatment of myelofibrosis (MF). Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).…